Over 10 years have passed since the first human papilloma virus (HPV) vaccine was licensed and recommended by the Advisory Council for Immunization Practices (ACIP) in the United States to prevent cervical cancer and other HPV-related outcomes.¹ Vaccine uptake for adolescent girls and boys aged 13 – 17 years lags behind those for other adolescent vaccines such as vaccines for tetanus, diphtheria, and pertussis; and meningococcal meningitis.² In 2015, only about 42% of adolescent girls and 28% of adolescent boys had received all three HPV vaccine doses recommended, while coverage with one or more vaccine doses was 63% for adolescent girls and nearly 50% for adolescent boys.² Coverage for adolescent boys lags behind girls because ACIP did not recommend routine vaccination of boys until 2011.³

Nearly 31,000 newly diagnosed cancer cases each year may be attributable to any HPV type.⁴ Fewer cases are diagnosed in men, but they experience a greater burden of oropharyngeal cancers each year than women.⁴ Among women, cervical cancer is the leading HPV-attributable cancer, followed by anal, vulvar, oropharyngeal, vaginal, and rectal cancers.⁴ Overall, nearly 12,000 women are diagnosed each year with cervical cancer, and over 4,000 women die of the disease.⁵ Although screening for cervical cancer using the Papanicolaou (Pap) test has dramatically reduced the cervical cancer burden in the US over the past several decades, over half of cervical cancer cases are among women who have never or rarely been screened.^6–8 Cervical cancer rates also vary by race/ethnicity and other demographic factors, and tend to be highest for Hispanic and African American women and women living in the southern US.^{4, 5} Widespread use of the HPV vaccine has the potential to reduce incidence and mortality from HPV-associated cancers, and narrow absolute differences in HPV-associated cancer incidence rates among Hispanic and African American women compared to non-Hispanic white women.⁹

In recent years, the Centers for Disease Control and Prevention (CDC) has worked to raise awareness of persistently low HPV vaccine uptake and address some of the issues that research has identified as contributing to low vaccine uptake, such as the lack of a strong recommendation by many health care providers or a risk-based approach toward vaccination; lack of awareness by parents and concerns about vaccine safety, or a desire to delay vaccination until older adolescence; and missed opportunities to administer the vaccine.^10–16 The 2014 President’s Cancer Panel Report¹⁷ highlighted similar barriers to HPV vaccine uptake, and provided several key goals and objectives to focus intervention efforts as a way to accelerate vaccine uptake. These initiatives have brought about prioritization of HPV vaccine interventions and new opportunities for collaboration across CDC and among other government agencies and organizations. One example includes collaboration between CDC’s National Comprehensive Cancer Control Program (NCCCP) and the National Center for Immunization and Respiratory Diseases (NCIRD).

CDC’s NCCCP funds all 50 states, the District of Columbia, seven tribes/tribal organizations, and 7 Pacific Island Jurisdictions and territories for comprehensive cancer control (CCC) activities (http://www.cdc.gov/cancer/ncccp/index.htm). Priorities of the NCCCP include primary prevention, secondary prevention and screening, and cancer survivorship, along with cross-cutting areas that include health equity, data and evaluation, and policy, systems, and environmental change approaches (http://www.cdc.gov/cancer/ncccp/about.htm). The CCC approach is built on the premise that bringing together cancer control stakeholders to collectively address the cancer burden in a jurisdiction creates synergy and allows for the leveraging of resources.¹⁸ NCCCP awardees create and implement data-informed cancer plans in collaboration with their CCC coalition or partnership. CCC coalition partners often include academic and medical partners, health systems, community-based organizations, businesses, other governmental organizations, and other health department divisions, such as NCIRD awardees. NCIRD provides funding to all 50 states, the District of Columbia, eight Pacific Island Jurisdictions and other territories, and selected city health departments (http://www.cdc.gov/vaccines/imz-managers/awardee-imz-websites.html) to administer the Vaccines for Children program, section 317 immunization grants, support immunization information systems, provide training and education to health professionals, and improve the uptake and delivery of vaccines.

Some awardees of both the NCIRD and NCCCP have worked together to add an objective to jurisdictional cancer plans about implementing interventions to promote HPV vaccine uptake. The purposes of this report are to identify which NCCCP awardees have recently been involved in interventions to promote HPV vaccine uptake and to describe the types of interventions they have implemented. This knowledge will help identify which intervention areas NCCCP awardees can be most effective in implementing and identify areas of the US in which collaboration between NCIRD and NCCCP awardees could be enhanced to address the burden of HPV-associated cancers.

Overall, 62% of all NCCCP awardees had planned or implemented at least one activity since 2013 to address low HPV vaccination coverage (Table 1). NCCCP awardees in the Midwest more frequently reported HPV vaccine activities and interventions (28%), followed by those in the South (23%, Table 1). Although most activities were reported by states, eight tribal organizations and Pacific Island Jurisdictions/territories also engaged in HPV-related activities (Table 1).

The majority of NCCCP awardees (86%) reported engaging in activities to educate the community, particularly parents, about the need for HPV vaccine (Table 1). Sixty-five percent of NCCCP awardees reported activities associated with provider education. Intervention planning before implementing interventions was reported by 44% of NCCCP awardees at some point during the time period. Relatively fewer awardees reported interventions that addressed provider reminders (7%), provider assessment and feedback or quality assurance (23%), client reminders (19%), or school-based vaccination (12%). Most NCCCP awardees used multiple strategies to conduct HPV interventions.

Nearly all NCCCP awardees engaged in HPV-related work reported interventions or activities that aligned with increasing vaccine acceptance (86%, Table 2). Over half of those described activities to address missed opportunities for vaccination (56%), and few reported interventions to maximize access to vaccination (23%). Examples of activities to increase vaccine acceptance included comprehensive media or communications campaigns, and training school nurses to provide education to parents or students about the vaccine. Interventions focused on reducing missed opportunities to vaccinate included provider education on making a strong vaccine recommendation to parents, and minimizing other missed opportunities to provide the vaccine by co-administering it with other adolescent vaccines, and taking advantage of other clinical encounters, such as sports physicals or back-to-school checkups. Some NCCCP awardees described efforts to implement client reminder systems within partner health systems or insurance companies, or through the state immunization information system. Provider reminder systems were another intervention to reduce missed opportunities. Examples of interventions to maximize access to vaccination services included school-based vaccination clinics, and educating college students about the HPV vaccine and its availability in the college health clinic.

Engagement in HPV-related activities was not entirely dependent on vaccination coverage (Figure 1) or cervical cancer incidence rates (Figure 2). Several NCCCP awardees within states that have relatively high HPV vaccination coverage for the first dose among adolescent females and those with the lowest coverage engaged in HPV-related activities (Figure 1). Although a number of NCCCP awardees in states with comparatively higher cervical cancer incidence rates reported activities to increase HPV vaccination coverage, some states with similarly high rates did not have any HPV-related activities (Figure 2).

Objectives and activities to increase HPV vaccine uptake were common in NCCCP awardees’ action plans over the 2013 – 2016 time period. These activities coincided with a large national effort to increase HPV vaccine uptake, as well as new funding opportunities to promote HPV vaccine, such as through Prevention and Public Health Funding (PPHF) for select immunization programs (https://pphf.hhs.gov/jsp/about.jsp). NCCCP awardees in states with PPHF-funded immunization programs more frequently reported multicomponent strategies, such as both public and provider education, and strategies directed at systems change (e.g. routine use of client reminders). However, some NCCCP awardees relied on either community education or provider education alone as a strategy, neither of which are recommended by The Community Guide as single intervention strategies due to insufficient evidence of effectiveness.²⁰ Although large scale media campaigns can result in a temporary increase in vaccination coverage rates, they may not result in sustained progress.²¹ However, some recent studies have found patient education implemented alone in community settings to be effective at increasing coverage for HPV vaccine and series completion.^22–24

NCCCP awardees frequently reported planning interventions in collaboration with immunization programs. Increasingly, partnerships are critical in public health to successfully implement and sustain interventions. In the Six Components Necessary for Effective Public Health Program Implementation, partnerships are identified as a key component of implementation.²⁵ When partnership building is successful and done through a mutually beneficial approach with shared vision and goals and collaborative decision-making, then synergy can arise for sustainable interventions.^26–28 Practically speaking, the right partners can bring expertise, resources (e.g. financial, donated staff time), and connections to other partners and sectors. In the case of efforts to increase HPV vaccine uptake, NCCCP awardees are logical partners for immunization programs not only because of the cancer prevention focus of the vaccine, but because they have connections to cancer coalitions that includes additional partners in the cancer community who can bring expertise and new avenues for interventions.

These findings reveal that some NCCCP awardees in states with historically low HPV vaccination coverage, such as Alaska, Kansas, New Jersey, and Tennessee, are implementing activities such as community or provider education.²⁹ In some instances, states with low HPV vaccination coverage are also states with high cervical cancer incidence and mortality, so directing public health efforts toward this area may be a strategic way to address the burden of cervical cancer and other HPV-associated cancers. For example, HPV vaccination coverage is typically lower in the South while cervical cancer incidence and death rates are higher in this geographic area compared to other US regions; therefore, encouraging NCCCP awardees in southern states to implement interventions may be a promising strategy to lower incidence and death rates.^{29, 30} However, some states with high cervical cancer burden reported no interventions to increase HPV vaccine uptake, representing a missed opportunity to further reduce disparities for a preventable disease.³¹ Rates of HPV vaccine initiation do tend to be higher among Hispanic and African American adolescent girls, and adolescents of lower socioeconomic status, so ensuring these adolescents receive timely reminders to complete the vaccination series may reduce existing cervical cancer disparities.² Thus, sustained, multicomponent interventions utilizing immunization and cancer control partners may have the most impact over time.^{20, 22}

In recent years, NCIRD has developed numerous resources to promote HPV vaccine that are directed to both providers and parents of adolescents (http://www.cdc.gov/hpv/). Provider resources include You are the Key to HPV Cancer Prevention continuing education series, factsheets, posters, and other resources (e.g. radio PSAs and video content). Resources were also developed to engage with HPV vaccination partners, including an HPV Vaccination Partner Toolkit that includes print materials, video and audio content, information on quality improvement and evidence-based interventions, and ideas for developing partner networks and engaging local partners.

Resources from other national efforts have supported NCCCP awardees to implement interventions along with their immunization partners. The CCC National Partners (http://www.cccnationalpartners.org/), which also include the National Cancer Institute (NCI) and the American Cancer Society (ACS), have prioritized promoting HPV vaccine. NCI has funded comprehensive cancer centers to conduct an environmental scan of HPV vaccine activities in their states, and to enhance linkages with coalitions and immunization and cancer control programs in their areas (http://healthcaredelivery.cancer.gov/hpvuptake/). CDC’s Division of Cancer Prevention and Control (DCPC) and the Immunization Services Division funded the ACS to develop and administer the National HPV Vaccination Roundtable (http://www.cancer.org/healthy/informationforhealthcareprofessionals/nationalhpvvaccinationroundtable/), a coalition of public, private, and voluntary organizations with expertise relevant to increasing HPV vaccination coverage in the US, as a way to reduce illness and death from HPV-associated cancers, through coordinated leadership, strategic planning, and advocacy. Finally, CDC’s DCPC has funded and administered a national educational awareness campaign since 2009, Inside Knowledge: Get the Facts About Gynecologic Cancer, which includes specific messages on HPV vaccination as prevention for cervical, vaginal, and vulvar cancers.³²

Our study has limitations. We relied on data reported by the program director or an individual or individuals to complete the tasks. NCCCP awardees vary in providing details that describe their activities and interventions; therefore, some interventions may not have been accurately classified because of data limitations. Additionally, not all NCCCP awardees with HPV vaccine-related interventions reported them for each year in our study period, and most systems-based interventions or interventions to maximize access to HPV vaccine were limited to a few local areas or provider practices and were not implemented population wide. In terms of the data search strategy, we focused on the most common terms that would yield relevant content; this could have limited our system’s search capabilities to capture all related interventions. Also, the use of one reviewer to review and code content may have been a limitation; however, the straightforward nature of this analysis has allowed for successful coding with one reviewer in previous similar studies using this data source.^{33, 34} One strength of our study is that CDMIS allows for current monitoring of activities and objectives which are captured in a fairly standardized manner.

It is advantageous for immunization programs and NCCCP awardees to collaborate on the goal of increasing HPV vaccine uptake. NCCCP awardees can leverage their network of partners and coalition members to plan activities, disseminate information, and implement interventions. It may be useful to define specific roles for NCCCP awardees, particularly in implementing multicomponent interventions, to avoid duplication of effort. While working in the vaccine arena, NCCCP awardees may have challenges, such as parental concerns about vaccine safety or early initiation of sexual activity among their children if they get vaccinated, or resistance by management or stakeholders who may not see the value in promoting HPV vaccine. Regular training by national organizations and ongoing dialogue with immunization partners about how to best address emerging issues may be helpful in these areas. NCCCP awardees in areas with a high cervical cancer burden may want to consider implementing multicomponent HPV vaccine interventions that include client reminders or provider assessment and feedback, and evaluate promising practices such as offering catchup HPV vaccination or systems changes that include adding the HPV vaccine to lists of recommended adolescent vaccines that may be provided by school nurses, athletic departments or camps. The goal is to raise HPV vaccination coverage to the level of other adolescent vaccines, and normalize HPV vaccine as a routine adolescent vaccine. NCCCP awardees can play a role through their cancer prevention and control expertise and access to partners in the health care community.